| Resolve Biosciences–North Rhine-Westphalia (govt): investment, 202210 financing round Series B totalling $71m incl co-investor NRW.BANK |
2022-10-24 |
| Resolve Biosciences–Patient Square Capital: investment, 202210 financing round Series B totalling $71m incl lead investor Patient Square Capital |
2022-10-24 |
| Resolve Biosciences–PS Capital Management: investment, 202210 financing round Series B totalling $71m incl existing + co-investor PS Capital |
2022-10-24 |
| Resolve Biosciences–SEVERAL: investment, 202210 financing round Series B $71m led by Patient Square Capital |
2022-10-24 |
| Stanford Univ–Resolve Biosciences: Molecular Cartography technology, 202210 supply to Stanford Medicine Dept of Genetics existent |
2022-10-24 |
| Univ Copenhagen–Resolve Biosciences: Molecular Cartography technology, 202210 supply to Novo Nordisk Foundation Center existent |
2022-10-24 |
| VIB–Resolve Biosciences: Molecular Cartography technology, 202210 supply to VIB existent as one of first customers |
2022-10-24 |
| HMNC–SEVERAL: investment, 202210 financing round 1st closing €14.3m from new + existing investors |
2022-10-20 |
| Roche–Hookipa: cancer immunotherapy, 202210–202401 collab + license $25m upfront + $930m milestones + royalties for HB-700 TERMINATED 1/24 |
2022-10-20 |
| Celeris Therapeutics–EU (govt): grant, 202210 EIC Accelerator grant €2.5m |
2022-10-19 |
| Celeris Therapeutics–EU (govt): investment, 202210 equity investment up to €10m from EIC Accelerator |
2022-10-19 |
| Nucleome Therapeutics–Merck (DE): investment, 202210 financing round Series A totalling £37.5m incl new + lead investor M Ventures |
2022-10-19 |
| Nucleome Therapeutics–SEVERAL: investment, 202210 financing round Series A £37.5m led by M Ventures |
2022-10-19 |
| Anokion–Pfizer: investment, 202210 equity investment $35m through Pfizer Breakthrough Growth Initiative |
2022-10-18 |
| Co.don–ReLive: investment, 202210–202301 acquisition €15m of assets of bankrupt Co.don AG by Rejuvenate GmbH renamed Co.don GmbH |
2022-10-17 |
| PBD Biotech–Foresight Group: investment, 202210 follow-on financing round totalling £2.4m incl co-lead investor Foresite Group via MEI Fund |
2022-10-17 |
| PBD Biotech–Mercia: investment, 202210 follow-on financing round totalling £2.4m incl co-lead investor Mercia via MEI Fund |
2022-10-17 |
| PBD Biotech–OTHER: investment, 202210 follow-on financing round totalling £2.4m incl private investors as co-investors |
2022-10-17 |
| PBD Biotech–SEVERAL: investment, 202210 follow-on financing round £2.4m co-led by Mercia + Foresight Group |
2022-10-17 |
| PBD Biotech–Univ Nottingham: investment, 202210 follow-on financing round totalling £2.4m incl co-investor Univ of Nottingham |
2022-10-17 |
| Bavaria (govt)–Osaka (govt): life sciences, 202210– collab third renewal of partnership of BioM + Osaka Bio Headquarters originally signed in 2011 |
2022-10-12 |
| Apollo Health Ventures–Trophic Communications: public relations, 202210 service existent by Trophic |
2022-10-11 |
| Focal Biosciences–Apollo Health Ventures: investment, 202210 founding investor Apollo HV launches Focal Biosciences with Paul Scherrer Institute |
2022-10-11 |
| Andera Partners–SEVERAL: investment, 202210 final closing of BioDiscovery 6 fund at €456m |
2022-10-10 |
| Immatics–SEVERAL: investment, 202210 underwritten offering $110m with 10.9m ordinary shares at $10.09/share |
2022-10-10 |
| Immunic–SEVERAL: investment, 202210 private placement $60m with $37.8m shares common stock plus $22.2m pre-funded warrants at $4.35/share |
2022-10-10 |
| PlasmidFactory–ArchiMed: investment, 202210 investment by ArchiMed MED Platform II Fund |
2022-10-07 |
| Cevec–Danaher: investment, 202210 acquisition of Cevec by Cytiva |
2022-10-06 |
| Irubis–EU (govt): investment, 202210 seed financing round totalling €2.8m incl co-investor EIC Fund |
2022-10-06 |
| Irubis–High-Tech Gründerfonds: investment, 202210 seed financing round totalling €2.8m incl co-lead investor HTGF |
2022-10-06 |
| Irubis–OTHER: investment, 202210 seed financing round totalling €2.8m incl business angels as co-investors |
2022-10-06 |
| Irubis–SEVERAL: investment, 202210 seed financing round €2.8m led by HTGF + Verve Ventures + Ventura BioMed Investors |
2022-10-06 |
| Irubis–TU Munich: investment, 202210 seed financing round totalling €2.8m incl co-investor Initiative for Industrial Innovators |
2022-10-06 |
| Irubis–Ventura Biomed Investors: investment, 202210 seed financing round totalling €2.8m incl co-lead investor Ventura Biomed Investors |
2022-10-06 |
| Irubis–Verve Capital Partners: investment, 202210 seed financing round totalling €2.8m incl co-lead investor Verve Ventures |
2022-10-06 |
| Araris Biotech–4BIO Ventures: investment, 202210 financing round totalling $24m incl existing + co-lead investor 4BIO Capital |
2022-10-04 |
| Araris Biotech–Bellevue: investment, 202210 financing round totalling $24m incl existing + co-lead investor Pureos Bioventures |
2022-10-04 |
| Araris Biotech–btov Partners: investment, 202210 financing round totalling $24m incl existing + co-investor btov Partners |
2022-10-04 |
| Araris Biotech–Institute for Follicular Lymphoma Innovation: investment, 202210 financing round totalling $24m incl new + co-investor IFLI |
2022-10-04 |
| Araris Biotech–Redalpine: investment, 202210 financing round totalling $24m incl existing + co-investor Redalpine |
2022-10-04 |
| Araris Biotech–Schroders: investment, 202210 financing round totalling $24m incl existing + co-investor Schroders Capital |
2022-10-04 |
| Araris Biotech–SEVERAL: investment, 202210 financing round $24m co-led by 4BIO Capital + Pureos Bioventures |
2022-10-04 |
| Araris Biotech–VI Partners: investment, 202210 financing round totalling $24m incl existing + co-investor VI Partners |
2022-10-04 |
| Araris Biotech–Wille Finance: investment, 202210 financing round totalling $24m incl new + co-investor Wille AG |
2022-10-04 |
| Sibylla Biotech–Helsinn: investment, 202210 financing round Series A totalling €23m incl co-investor 3B Future Health Fund II S.C.A. SICAV-RAIF |
2022-10-04 |
| Sibylla Biotech–SEVERAL: investment, 202210 financing round Series A €23m led by V-Bio Ventures |
2022-10-04 |
| Sibylla Biotech–Trophic Communications: public relations, 202210 service existent by Trophic |
2022-10-04 |
| Sibylla Biotech–VI Partners: investment, 202210 financing round Series A totalling €23m incl co-investor VI Partners |
2022-10-04 |
| Assay.Works–Partex: investment, 202209–202210 acquisition €na of Assay.Works by Partex |
2022-09-29 |
| Xund Solutions–Lana Ventures: investment, 202209 seed financing round totalling €6m incl co-investor Lana Ventures |
2022-09-29 |
| Xund Solutions–MassMutual: investment, 202209 seed financing round totalling €6m incl co-lead investor MassMutual Ventures |
2022-09-29 |
| Xund Solutions–MMC Ventures: investment, 202209 seed financing round totalling €6m incl co-lead investor MMC Ventures |
2022-09-29 |
| Xund Solutions–Roche: investment, 202209 seed financing round totalling €6m incl co-investor RoX Health |
2022-09-29 |
| Xund Solutions–SEVERAL: investment, 202209 seed financing round €6m co-led by MMC Ventures + MassMutual Ventures |
2022-09-29 |
| GS Bavaria–High-Tech Gründerfonds: investment, 202209 seed financing round totalling €7-figure incl lead investor HTGF |
2022-09-28 |
| GS Bavaria–OTHER: investment, 202209 seed financing round totalling €7-figure incl renowbed business angels |
2022-09-28 |
| GS Bavaria–SEVERAL: investment, 202209 seed financing round €7-figure led by HTGF |
2022-09-28 |
| Valneva–SEVERAL: investment, 202209–202210 private placement €100-45m of 20.5m ordinary shares at €4.9/share |
2022-09-28 |
| Valneva–SEVERAL: investment, 202209–202210 public offering $3.57m of 375k ADSs (each = 2 ordinary shares) at $9.51/ADS |
2022-09-28 |
| BioDGraft–NLC Ventures: investment, 202209 existent seed investor NLC |
2022-09-27 |
| Roche–Arsenal Biosciences: CAR-T cell therapies, 202209– collab discovery $70m upfront + milestones CAR T-cell therapies for cancer with Genentech |
2022-09-27 |
| Kupando–Brandenburg (govt): investment, 202209 financing round Series A totalling €13m incl co-investor Brandenburg Kapital |
2022-09-26 |
| Kupando–High-Tech Gründerfonds: investment, 202209 financing round Series A totalling €13m incl co-investor HTGF |
2022-09-26 |
| Kupando–LifeCare Partners: investment, 202209 financing round Series A totalling €13m incl co-lead investor LifeCare Partners |
2022-09-26 |
| Kupando–OTHER: investment, 202209 financing round Series A totalling €13m incl undisclosed family offices as co-investors |
2022-09-26 |
| Kupando–Remiges Ventures: investment, 202209 financing round Series A totalling €13m incl lead investor Remiges Ventures |
2022-09-26 |
| Kupando–SEVERAL: investment, 202209 financing round Series A €13m led by Remiges Ventures + co-led by LifeCare Partners |
2022-09-26 |
| Kupando–Ventura Biomed Investors: investment, 202209 financing round Series A totalling €13m incl co-investor Venture Biomed Investors |
2022-09-26 |
| Evotec–Adapsyn Biotechnology: drug discovery, 202209– strategic collab €na providing Evotec with access to drug-like small molecules for screening |
2022-09-21 |
| Hedera Dx–Air Street Capital: investment, 202209 seed financing round totalling €14m incl co-investor Air Street Capital |
2022-09-21 |
| Hedera Dx–Amino Collective: investment, 202209 seed financing round totalling €14m incl co-investor Amino Collective |
2022-09-21 |
| Hedera Dx–Grids Capital: investment, 202209 seed financing round totalling €14m incl co-investor Grids Capital |
2022-09-21 |
| Hedera Dx–Inventure: investment, 202209 seed financing round totalling €14m incl co-investor Inventure |
2022-09-21 |
| Hedera Dx–SEVERAL: investment, 202209 seed financing round €14m led by Top Harvest Capital |
2022-09-21 |
| Hedera Dx–Top Harvest Capital: investment, 202209 seed financing round totalling €14m incl lead investor Top Harvest Capital (Adam Ghobarah) |
2022-09-21 |
| Merck (DE)–NMS Group: PARP inhibitor, 202209– collab + license option for PARP1 selective inhibitor NMS-293 |
2022-09-21 |
| Avelo–Arve Capital: investment, 202209 seed financing round totalling CHF2.2m incl co-investor Arve Capital |
2022-09-20 |
| Avelo–Occident: investment, 202209 seed financing round totalling CHF2.2m incl lead investor Occident |
2022-09-20 |
| Avelo–OTHER: investment, 202209 seed financing round totalling CHF2.2m incl several MedTech angel investors as co-investors |
2022-09-20 |
| Avelo–Privilège Ventures: investment, 202209 seed financing round totalling CHF2.2m incl co-investor Privilège Ventures |
2022-09-20 |
| Avelo–SEVERAL: investment, 202209 seed financing round CHF2.2m led by Occident |
2022-09-20 |
| Avelo–Zürcher Kantonalbank: investment, 202209 seed financing round totalling CHF2.2m incl co-investor ZKB |
2022-09-20 |
| EFOS (SI)–ECBF: investment, 202209 financing round Series B totalling €10m incl lead investor European Circular Bioeconomy Fund |
2022-09-20 |
| EFOS (SI)–SEVERAL: investment, 202209 financing round Series B €10m led by ECBF |
2022-09-20 |
| Nuvisan–Gates Foundation: grant, 202209– grant $9.6m for RnD on non-hormonal contraceptive medicines at Nuvisan ICB GmbH |
2022-09-20 |
| Nilogen Oncosystems–Scailyte: personalised medicine, 202209 collab existent developm omics platform for analyzing tumour tissues for I-O developm |
2022-09-19 |
| Scailyte–Mirabaud: investment, 202209 financing round Series A totalling CHF6m incl new investor Mirabaud bank |
2022-09-19 |
| Scailyte–OTHER: investment, 202209 financing round Series A totalling CHF6m incl Swiss family office as new investor |
2022-09-19 |
| Scailyte–SEVERAL: investment, 202209 financing round Series A CHF6m with Swiss family office + Mirabaud bank + existing investors |
2022-09-19 |
| Scailyte–Swisscom: investment, 202209 financing round Series A totalling CHF6m incl existing investor Swisscom Ventures |
2022-09-19 |
| Versantis–Genfit: investment, 202209– acquisition CHF40m upfront + CHF65m milestones + 1/3 of net proceeds of eventual PRV |
2022-09-19 |
| Aignostics–Berlin (govt): investment, 202209 financing round Series A totalling €14m incl existing + co-investor VC Fonds Technologie (IBB Ventures) |
2022-09-15 |
| Aignostics–Boehringer: investment, 202209 financing round Series A totalling €14m incl existing + co-investor BIVF |
2022-09-15 |
| Aignostics–Carma Fund: investment, 202209 financing round Series A totalling €14m incl new + co-investor Carma Fund |
2022-09-15 |
| Aignostics–High-Tech Gründerfonds: investment, 202209 financing round Series A totalling €14m incl existing + co-investor HTGF |
2022-09-15 |
| Aignostics–MC Services: public relations, 202209 service existent by MC Services |
2022-09-15 |
| Aignostics–SEVERAL: investment, 202209 financing round Series A €14m led by Wellington Partners |
2022-09-15 |
| Aignostics–Wellington Partners: investment, 202209 financing round Series A totalling €14m incl new + lead investor Wellington Partners |
2022-09-15 |
| Kuros–Alpha Capital: investment, 202209 capital increase totalling CHF6m incl investor Pegasus Global Opportunity Fund Ltd |
2022-09-15 |
| Kuros–Optiverder: investment, 202209 capital increase totalling CHF6m incl investor Optiverder BV |
2022-09-15 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 12 13 14 ... 39 40 41 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
